July 26th 2024
Study explores the role of the gut microbiome in shaping immune responses and efficacy of immune checkpoint inhibitors in the treatment of multiple cancer types.
Columvi Combination Shows Significant Survival Benefit Treating R/R DLBCL in Phase III STARGLO trial
June 19th 2024Columvi with gemcitabine and oxaliplatin (GemOx) achieved statistically significant and clinically meaningful outcomes treating relapsed or refractory diffuse large B-cell lymphoma compared to MabThera/Rituxan plus GemOx.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.